Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TK1 | P04183 | 5/20 | 0.60 |
| ▸ | POLB | P06746 | 3/20 | 0.56 |
| ▸ | POLA1 | P09884 | 1/20 | 0.56 |
| ▸ | POLD1 | P28340 | 1/20 | 0.56 |
| ▸ | TYMS | P04818 | 1/20 | 0.50 |
| ▸ | RNASE1 | P07998 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18119004 | 0.91 | TK1 (0.59) | TK1POLBPOLA1POLD1RNASE1 | |
| SCHEMBL30171374 | 0.90 | TK1 (0.69) | TK1POLBPOLA1POLD1TYMS | |
| SCHEMBL7243145 | 0.89 | TK1 (0.62) | TK1POLBPOLA1POLD1RNASE1 | |
| SCHEMBL16426201 | 0.88 | TK1 (0.59) | TK1RNASE1 | |
| SCHEMBL15236309 | 0.88 | TK1 (0.59) | TK1RNASE1 | |
| SCHEMBL12360859 | 0.88 | TK1 (0.59) | TK1RNASE1 | |
| SCHEMBL20857214 | 0.88 | TK1 (0.65) | TK1POLBPOLA1POLD1RNASE1 | |
| SCHEMBL24370822 | 0.88 | POLB (0.72) | TK1POLBPOLA1POLD1TYMS | |
| SCHEMBL2384264 | 0.88 | POLB (0.62) | TK1POLBPOLA1POLD1RNASE1 | |
| SCHEMBL29355784 | 0.88 | TK1 (0.67) | TK1POLBPOLA1POLD1RNASE1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8962670-B2 | Anti-cancer agents | UWM RESEARCH FOUNDATION, INC. (US) | 2015-02-24 | — | — | US | disclosed |
| US-8637490-B2 | Anti-cancer agents | UWM RESEARCH FOUNDATION, INC. (US) | 2014-01-28 | — | — | US | disclosed |
| US-8637490-B2 | Anti-cancer agents | UWM RESEARCH FOUNDATION, INC. (US) | 2014-01-28 | — | — | US | disclosed |
| US-20130045949-A1 | ANTI-CANCER AGENTS | UWM RESEARCH FOUNDATION, INC. (US) | 2013-02-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130045949-A1 | ANTI-CANCER AGENTS | TP53, MCL1, HRAS | TK1 164/4885POLB 650/4885POLA1 469/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.